Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Lone-star-bio symbols : RETA save search
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 5.82%
H: 7.57%
C: -7.32%
berubicin treatment pharmaceuticals glioblastoma study
CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy
Published: 2023-11-22 (Crawled : 15:00) - biospace.com/
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 3.35%
H: 25.0%
C: 4.17%
berubicin ongoing pharmaceuticals study
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-08-03 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.57%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 0.93%
H: 3.24%
C: 1.39%
berubicin update treatment ongoing pharmaceuticals trial glioblastoma study
CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-05-25 (Crawled : 20:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.18%
H: 0.79%
C: -2.78%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: -4.52%
H: 6.84%
C: 4.74%
berubicin treatment pharmaceuticals glioblastoma study
Over 100 Patients Now Enrolled in CNS Pharmaceuticals’ (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2023-04-10 (Crawled : 16:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.23%
H: 1.81%
C: 1.25%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: -4.79%
H: 8.16%
C: 4.9%
berubicin treatment 100 glioblastoma study
CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2023-04-06 (Crawled : 14:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.79%
H: 0.86%
C: 0.6%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 53.58%
H: 6.02%
C: -43.6%
approval berubicin treatment pharmaceuticals global trial
Reata Pharmaceuticals Announces Participation in the Barclays Global Healthcare Conference
Published: 2023-03-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.96%
H: 1.07%
C: -1.66%
pharmaceuticals global conference
CNS Pharmaceuticals Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)
Published: 2022-12-08 (Crawled : 15:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.34%
H: 1.98%
C: -1.85%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 2.92%
H: 0.03%
C: -3.66%
treatment ongoing pharmaceuticals trial berubicin glioblastoma
Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference
Published: 2022-11-10 (Crawled : 00:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 4.31%
H: 1.2%
C: -5.49%
pharmaceuticals conference immunology
Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs
Published: 2022-11-08 (Crawled : 12:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 3.15%
H: 18.92%
C: 11.92%
financial update results
Reata Pharmaceuticals, Inc. to Report Third Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on November 8, 2022
Published: 2022-10-31 (Crawled : 00:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.4%
H: 11.31%
C: 8.42%
report financial update results
Reata Pharmaceuticals Announces Participation in the Citi 17th Annual BioPharma Conference
Published: 2022-09-06 (Crawled : 23:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: -5.21%
biopharma conference
Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia
Published: 2022-08-09 (Crawled : 11:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.21%
H: 0.13%
C: -10.18%
treatment drug extension application review friedreich’s ataxia
Reata Pharmaceuticals, Inc. to Report Second Quarter 2022 Financial Results and to Provide an Update on Clinical Development Programs on August 8, 2022
Published: 2022-08-01 (Crawled : 11:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.56%
H: 4.98%
C: -1.13%
report update results
CNS Pharmaceuticals Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Published: 2022-06-23 (Crawled : 13:20) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -0.09%
H: 3.99%
C: 3.0%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 32.07%
H: 1.89%
C: -24.85%
treatment fda ongoing trial approval berubicin potential
CNS Pharmaceuticals Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Published: 2022-06-08 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.36%
H: 6.26%
C: 1.73%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 0.98%
H: 3.23%
C: -0.9%
ongoing trial presentation berubicin potential designation
CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Published: 2022-05-18 (Crawled : 17:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -4.6%
H: 6.23%
C: 2.33%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: -6.49%
H: 14.87%
C: 7.96%
presentation
CNS Pharmaceuticals Receives Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.2%
H: 0.68%
C: -0.26%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 8.65%
H: 0.0%
C: -6.34%
treatment approval berubicin potential glioblastoma
CNS Pharmaceuticals Receives Approval from France Ethics Committee and Competent Authority for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Published: 2022-04-06 (Crawled : 13:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: -1.09%
H: 1.8%
C: 0.45%
CNSP | News | $0.2002 -4.67% -4.9% 76K
|
Health Technology
|
| O: 5.16%
H: 7.69%
C: 6.16%
treatment approval berubicin potential glioblastoma
Reata Pharmaceuticals Completes Rolling Submission of New Drug Application for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Published: 2022-03-31 (Crawled : 22:00) - biospace.com/
RETA | $172.36 0.02% 0.03% 0
|
Health Technology
|
| O: 2.04%
H: 6.09%
C: 3.97%
treatment drug application submission friedreich’s ataxia
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.